Protagonist Therapeutics, Inc. is a biopharmaceutical company focused on peptide therapeutics. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its two peptides derived from its proprietary discovery technology platform, rusfertide and icotrokinra, are in advanced Phase III clinical development. Its rusfertide (PTG-300) is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. Icotrokinra, an orally delivered IL-23R specific antagonist for the potential treatment of psoriasis, psoriatic arthritis (PsA), ulcerative colitis and inflammatory bowel disease (IBD) indications. The Company also has a pre-clinical stage oral drug discovery program addressing clinically and commercially validated targets, including the IL-17 oral peptide antagonist PN-881, an oral hepcidin program, and an oral obesity program.
Growing
The company is in a growing phase, with the latest annual income totaling USD 46.02M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 46.02M.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Undervalued
The company’s latest PE is -67.42, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 76.23M shares, decreasing 4.07% quarter-over-quarter.
Held by Stanley Druckenmiller
Star Investor Stanley Druckenmiller holds 164.66K shares of this stock.